For decades, Bristol Myers Squibb (BMS) has cemented its status as a titan of the pharmaceutical industry by orchestrating high-stakes acquisitions. From its roots in 19th-century mergers to the game-changing $74 billion purchase of Celgene in 2019, the company has consistently utilized aggressive M&A to secure its leadership in oncology and cell therapy. Yet, as the industry landscape shifts, BMS is turning its gaze toward the most daunting challenge in modern medicine: the human brain.
BMS is currently executing a calculated pivot into neuroscience, a field historically defined by high failure rates and immense clinical complexity. Armed with a $14 billion acquisition of Karuna Therapeutics—and its flagship schizophrenia drug, Cobenfy—the company is aiming to build a sustainable psychiatry and neurology franchise. This strategic expansion represents a departure from its oncology-heavy past, signaling a long-term commitment to decoding the complexities of Alzheimer’s disease, bipolar disorder, and beyond.
A Legacy Forged in Mergers
To understand the current ambition of Bristol Myers Squibb, one must look at its history of structural evolution. The company’s DNA is composed of repeated consolidation, transforming it into a global powerhouse capable of funding the R&D cycles required for neuroscience.
The acquisition of Celgene was not merely a purchase; it was a repositioning of the company as a leader in blood cancer and immunotherapy. However, as the patent cliffs for older products loom and the oncology market becomes increasingly crowded, BMS has identified neuroscience as a primary growth vector. By integrating smaller, innovative firms like Karuna, BMS is attempting to replicate its previous success in oncology within the neurology space, leveraging its robust clinical development infrastructure to scale treatments that were previously confined to boutique biotech pipelines.
The Neuroscience Portfolio: From Schizophrenia to Alzheimer’s
The centerpiece of this new era is Cobenfy. Approved in 2024, the drug represents a first-of-its-kind mechanism for treating schizophrenia, targeting muscarinic receptors rather than the dopamine receptors that have dominated psychiatry for decades. While initial sales have been characterized as "modest" by market analysts, BMS leadership views the drug as the cornerstone of a broader psychiatry franchise.
The clinical pipeline for Cobenfy is expansive. Researchers are currently evaluating its efficacy in treating bipolar mania and the debilitating psychosis and agitation often associated with Alzheimer’s disease. For investors, the upcoming readout for the Alzheimer’s psychosis study is a bellwether event. Analysts, such as William Blair’s Matt Phipps, note that this data will be critical in determining whether Cobenfy can evolve from a niche treatment into a standard of care.
Expert Perspectives: The Science of Neuro-Degeneration
BioPharma Dive sat down with Ken Rhodes, Head of Neuroscience Research, and Laura Gault, Head of Neuroscience Development, to discuss the technical and philosophical challenges of their new mission.
The Amyloid Hypothesis and Beyond
The "amyloid hypothesis"—the theory that beta-amyloid plaques are the primary driver of Alzheimer’s—has been the subject of fierce debate. Critics argue that targeting amyloid has yielded mixed results, yet for BMS, the science remains compelling.
"The causal biology linking amyloid to Alzheimer’s disease is incontrovertible," says Rhodes. "Patients who have mutations that lead to higher amyloid production develop the disease at earlier ages. We see earlier intervention as the key to better patient outcomes."
However, BMS is not relying solely on amyloid. Gault emphasizes a "balanced and diversified" pipeline. "We are looking at both symptomatic and disease-modifying approaches," she explains. The company is actively investigating tau protein, which is closely linked to the formation of neurofibrillary tangles and the progression of cognitive impairment. Furthermore, BMS is exploring neuroinflammation—an area that has gained significant traction in recent genetic research—as a potential secondary target.
Innovation via "Shuttle" Technologies
One of the most significant barriers in neuroscience is the blood-brain barrier (BBB), which prevents the vast majority of therapeutic molecules from entering the brain. Gault notes that current "naked" antibodies are inefficient, often with less than 0.5% of the dose successfully crossing the barrier.
"There is a whole generation of antibodies in development that are attaching to transporters to cross this barrier," Gault explains. By utilizing these "shuttle" technologies, BMS believes it can increase the concentration of drugs in the brain, potentially clearing plaque more effectively while minimizing the side effects associated with earlier anti-amyloid therapies.
Clinical Rigor: Redefining the "Good Experiment"
The high cost and failure rate of Alzheimer’s trials are notorious. To mitigate risk, BMS has shifted its focus toward earlier, more granular clinical readouts.
"We focus a lot on: How do we get as early a read as possible on whether we’re on the right track?" says Rhodes. Rather than moving directly into massive, expensive Phase 3 trials, the team is prioritizing proof-of-concept testing. This includes demonstrating that a molecule successfully engages its target biology and that the drug is physically reaching the brain.
"Each of these steps increases our probability of success," Gault adds. "It is about building a body of evidence that justifies further investment."
Implications for the Future of Psychiatry
The challenge in psychiatry, according to the BMS team, is the lack of standardized biomarkers compared to the progress made in oncology or even Alzheimer’s research.
"In psychiatry, I can’t point to a large dataset that’s available to help us understand a biomarker approach," Gault admits. To bridge this gap, BMS is advocating for "pre-competitive" collaboration—an industry-wide effort to pool data and define new endpoints. The company is exploring the use of EEG and functional MRI to observe changes in brain circuitry, providing a more objective measure of drug efficacy than subjective patient-reported outcomes.
Despite some market skepticism regarding the commercial uptake of Cobenfy, BMS leadership remains undeterred. "It hasn’t changed our interest at all," Gault asserts. "We have a high degree of confidence in Cobenfy and what it can deliver. We are excited to continue to build that breadth in our pipeline."
Looking Ahead: The Role of Biomarkers
The ultimate goal for BMS is a future where Alzheimer’s risk is managed through routine screenings. Rhodes envisions a world where a simple blood test provides a risk score for neurodegenerative diseases, much like cholesterol levels signal cardiovascular risk.
"Incredible investments are being made in biomarker discovery," Rhodes says. "These tools are going to be absolutely essential because I don’t think we can run a 10-year clinical study if we don’t know the patient’s risk of progression."
By combining its financial strength with a rigorous, evidence-based approach to neuroscience, Bristol Myers Squibb is positioning itself at the vanguard of a medical revolution. While the path ahead is fraught with the unique difficulties of the human brain, the company’s pivot suggests that it is not looking for a quick win, but a long-term transformation of how we treat the most challenging diseases of the 21st century. As the data from their ongoing clinical trials matures, the industry will be watching closely to see if BMS can once again turn a high-risk gamble into a cornerstone of its global success.
About the Author
